Patents by Inventor Mark Thomas Miller

Mark Thomas Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20250205232
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Application
    Filed: July 17, 2024
    Publication date: June 26, 2025
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 12324802
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: June 10, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy J. Clemens, William Schulz Bechara, Brett C. Bookser, Thomas Cleveland, Timothy R. Coon, Michel Gallant, Peter Grootenhuis, Sara Sabina Hadida Ruah, Julie Laterreur, Mark Thomas Miller, Prasuna Paraselli, Yeeman K. Ramtohul, Thumkunta Jagadeeswar Reddy, Claudio Sturino, Lino Valdez, Jinglan Zhou, Minson Baek
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20250179091
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: August 5, 2024
    Publication date: June 5, 2025
    Inventors: Jeremy J. Clemens, Brett C. Bookser, Thomas Cleveland, Timothy R. Coon, Michel Gallant, Peter Diederik Jan Grootenhuis, Sara Sabina Hadida Ruah, Julie Laterreur, Vito Melillo, Mark Thomas Miller, Prasuna Paraselli, Yeeman K. Ramtohul, Thumkunta Jagadeeswar Reddy, Claudio Sturino, Lino Valdez, Jinglan Zhou, Minson Baek, William Schulz Bechara
  • Crystalline forms of CFTR modulators
    Patent number: 12319693
    Abstract: Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: October 24, 2023
    Date of Patent: June 3, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Yi Shi, Kevin J. Gagnon, Jicong Li, Jennifer Lu, Ales Medek, Muna Shrestha, Michael Waldo, Beili Zhang, Carl L Zwicker, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20250171469
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: August 1, 2024
    Publication date: May 29, 2025
    Inventors: Alexander Russell ABELA, Jeremy J. CLEMENS, Peter Diederik Jan GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Jason McCARTNEY, Mark Thomas MILLER, Fabrice Jean Denis PIERRE, Joe Anh TRAN, Jinglan ZHOU
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20250122218
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: February 7, 2023
    Publication date: April 17, 2025
    Inventors: Jeremy J. CLEMENS, Alexander R. ABELA, Brett C. BOOKSER, Thomas CLEVELAND, Timothy R. COON, Michel GALLANT, Sara Sabina HADIDA RUAH, Peter GROOTENHUIS, Yoshihiro ISHIHARA, Julie LATERREUR, Jason MCCARTNEY, Mark Thomas MILLER, Prasuna PARASELLI, Yeeman K. RAMTOHUL, Thumkunta Jagadeeswar REDDY, William SCHULZ BECHARA, Claudio STURINO, Joe A. TRAN, Lino VALDEZ, Jinglan ZHOU, Ramkrishna DE
  • Modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 12269831
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: April 8, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy J. Clemens, Brett C. Bookser, Thomas Cleveland, Timothy R. Coon, Michel Gallant, Peter Diederik Jan Grootenhuis, Sara Sabina Hadida Ruah, Julie Laterreur, Vito Melillo, Mark Thomas Miller, Prasuna Paraselli, Yeeman K. Ramtohul, Thumkunta Jagadeeswar Reddy, Claudio Sturino, Lino Valdez, Jinglan Zhou, Minson Baek, William Schulz Bechara
  • CRYSTALLINE FORMS OF CFTR MODULATORS
    Publication number: 20250051326
    Abstract: Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 13, 2025
    Inventors: Yi Shi, Kevin J. Gagnon, Jicong Li, Jennifer Lu, Ales Medek, Muna Shrestha, Michael Waldo, Beili Zhang, Carl L. Zwicker, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 12168009
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: December 17, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS
    Publication number: 20240400544
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 5, 2024
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Elizabeth Mary BECK, Robert PULLIN, Gorka ETXEBARRIA JARDI, Dean STAMOS, Yvonne SCHMIDT, Joseph PONTILLO, Stephen Andrew THOMSON, David Matthew SHAW, Nadia M. AHMAD, Lidio Marx CARVALHO MEIRELES, Sarah SKERRATT, Sara S. HADIDA RUAH, Timothy Donald NEUBERT, Dennis James HURLEY, Alexander KINTZER, Steven John DURRANT, Christopher WRAY, Anisa Nizarali VIRANI, Kiri NORTH, Reece JACQUES, Mark Thomas Miller, Jinglan ZHOU, Ronald Marcellus KNEGTEL, Ewa Iwona CHUDYK, Joanne Louise PINDER, Bruno Artur SOUSA, James DODD, Michael Edward O'DONNELL, Bhairavi GALAN, Rebecca E. STEVENS
  • SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS
    Publication number: 20240368135
    Abstract: Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 7, 2024
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Elizabeth Mary BECK, Robert PULLIN, Gorka ETXEBARRIA JARDI, Dean STAMOS, Yvonne SCHMIDT, Joseph PONTILLO, Stephen Andrew THOMSON, David Matthew SHAW, Nadia M. AHMAD, Lidio Marx CARVALHO MEIRELES, Sarah SKERRATT, Sara S. HADIDA RUAH, Mark Thomas Miller, Timothy Donald NEUBERT, Dennis James HURLEY, Jinglan ZHOU, Alexander KINTZER, Steven John DURRANT, Christopher WRAY, Anisa Nizarali VIRANI, Kiri NORTH, James DODD, Reece JACQUES, Stephen Michael GEDDIS, Bhairavi GALAN, Ronald Marcellus KNEGTEL, Ewa Iwona CHUDYK, Joanne Louise PINDER, Bruno Artur SOUSA, Rebecca E. STEVENS, Miranda Adele WRIGHT, Heather Clare TWIN, James Jun Bon MUI
  • Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators
    Publication number: 20240368189
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: October 10, 2023
    Publication date: November 7, 2024
    Inventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Process of making CFTR modulators
    Patent number: 12122788
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 4, 2023
    Date of Patent: October 22, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20240150377
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: May 9, 2024
    Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Timothy A. DWIGHT, Lev Tyler Dewey FANNING, Bryan A. FRIEMAN, Peter GROOTENHUIS, Anton V. GULEVICH, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Paul KRENITSKY, Vito MELILLO, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Johnny UY, Lino VALDEZ, Troy VICKERS, Jinglan ZHOU
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20240018161
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 18, 2024
    Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Andrew DINH, Timothy A. DWIGHT, Lev Tyler Dewey FANNING, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Paul KRENITSKY, Mark Thomas MILLER, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Lino VALDEZ, Jinglan ZHOU
  • Crystalline forms of CFTR modulators
    Patent number: 11873300
    Abstract: Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: January 16, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Yi Shi, Kevin J. Gagnon, Jicong Li, Jennifer Lu, Ales Medek, Muna Shrestha, Michael Waldo, Beili Zhang, Carl L. Zwicker, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
    Patent number: 11866450
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: January 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20230416275
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: December 28, 2023
    Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy A. DWIGHT, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Mark Thomas MILLER, Alina SILINA, Jinglan ZHOU
  • PROCESS OF MAKING CFTR MODULATORS
    Publication number: 20230399343
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 4, 2023
    Publication date: December 14, 2023
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20230382925
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 30, 2023
    Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Timothy A. DWIGHT, Lev Tyler Dewey FANNING, Bryan A. FRIEMAN, Peter GROOTENHUIS, Anton V. GULEVICH, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Paul KRENITSKY, Vito MELILLO, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Johnny UY, Lino VALDEZ, Jinglan ZHOU